MP NEWS:Pithampur. Rushan Pharma, a leading pharmaceutical company in Madhya Pradesh, recently achieved an important milestone by starting its state-of-the-art API Plant at Peethampur, Special Economic Zone (SEZ), Madhya Pradesh. Has attained. The company is committed to improving healthcare globally and becoming a leader in pain management and addiction solutions worldwide. This achievement reflects Rusan Pharma’s unwavering dedication towards addressing the problems caused by drug, alcohol and tobacco addiction as well as contributing to the growth of the Indian pharmaceutical industry.
Keeping in mind the vision of continuous growth and technological advancement, a total investment of up to Rs 300 crore will be made in this plant in two phases. This investment will not only reflect Rusan Pharma’s commitment, but will also boost the growth of the pharmaceutical industry. The plant is designed to meet stringent international regulatory guidelines ensuring the highest level of approval. This plant has a production capacity of 400 metric tons of API annually. Also, it will significantly contribute to Rusan Pharma’s growth and upcoming plans, which will diversify its portfolio as well as expand its reach in India and other countries. More than 3000 contract workers were employed during the construction phase of the Pithampur plant. After its full launch, more than 300 employees will be provided direct employment and more than 500 indirect employment opportunities will be created in the coming few years.
capable of increasing capacity
Dr. Naveen Saxena, Founder and Chairman, Rusan Pharma, said, “This latest API plant at Pithampur will enable Rusan to scale up our existing API capacity while ensuring the supply of critical APIs in India and globally. to meet the growing demand for our addiction treatment and pain management products. Rusan has been investing in this space for over 30 years and has been a leader in making addiction treatment accessible. We believe that people There should be an equal right to high-quality health care. Our goal is to provide access to everyone who seeks treatment for addiction and pain management.”
This newest plant is located in the centrally located Special Economic Zone (SEZ) of Pithampur. It will get the benefit of assistance and subsidy provided by the Madhya Pradesh State Government. This place will become a medium to streamline not only trade operations but also export related processes through dry port. Thus, it is poised to be the best option for Rusan Pharma’s plans going forward. Located in a dedicated pharmaceutical area, the plant provides a clean environment, reducing the risk of pollution from other industries in the area.
Elaborating on the initiative, Dr. Kunal Saxena, Managing Director, Rusan Pharma, said, “At Rusan, we exemplify the ‘Make in India’ initiative, especially in the controlled substances sector With an investment of approximately Rs 300 crore in two phases, this latest API plant will expand our current API manufacturing capacity at Pithampur to 400 MT from 40 MT at Ankleshwar. Our new plant will have five modular API manufacturing capacity. blocks, with dedicated suites for finished API manufacturing. This maintains complete control over the quality of our products and reduces our dependence on imports. Also, it reflects our commitment to excellence It incorporates advanced automation and compliant software, enabling us to maintain tight environmental controls and adopt paper-less manufacturing. This will help us reach a wider population and provide essential services more cost-effectively. Will be able to produce medicines.”
Current GMP approval for Rusan’s API and finished formulation plants has the capacity to meet 90% of the world’s demand. Health Canada, TGA-Australia, Safra-South Africa, EU, UAE and Russia are some of the names whose GMP approvals the company has received.
